# A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

> **NCT02083185** · PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 136 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Relugolix
- **DRUG:** Leuprorelin

## Key facts

- **NCT ID:** NCT02083185
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-26
- **Primary completion:** 2016-01-01
- **Final completion:** 2017-02-23
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2018-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02083185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02083185, "A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02083185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*